

Dennis K. Fuller, PharmD.

Office Addresses:

Department of Pharmaceutical Services
University Medical Center of Southern Nevada
1800 W. Charleston Boulevard
Las Vegas, NV 89102
(702) 383-2606 - Office
(702) 383-2052 - Fax
E-mail Address: dennis.fuller@umcsn.com

Wellness Center
2300 S. Rancho Drive Suite #205
Las Vegas, NV 89102
(702) 383-2691 -Office
(702) 388-4186 - Fax

Nevada Access to Research and Education Society
Nevada AIDS Research and Education Society
2300 S. Rancho Dr. Suite #203
Las Vegas, Nevada 89102
(702) 384-9101 - Office
(702) 384-9109- Fax

E-mail address:

dfdrugdoc@cox.net
Dennis.fuller@umcsn.com

EDUCATION AND TRAINING

1990	Doctor of Pharmacy University of Arizona College of Pharmacy Tucson, Arizona
1989	Bachelor of Science Pharmacy University of Arizona College of Pharmacy Tucson, Arizona
1986	Chemistry Major University of Arizona Tucson, Arizona

PROFESSIONAL CERTIFICATION AND LICENSURE

July 2001 - Present	IATA Regulation and Hazardous Material (49CFR and Canadian TDR) Certification Program Saf-T-Pak Inc Course in Shipping Hazardous Goods Las Vegas, Nevada
July 1994 - Present	Allied Health Professional Prescriptive Privileges by Protocol University Medical Center of Southern Nevada Las Vegas, NV
October 1993 - Jan 2001	Board Certified Pharmacotherapy Specialist Board of Pharmaceutical Specialties
June 1990 - Present	Registered Pharmacist, Nevada License Number 10382
October 1989-Present	Registered Pharmacist, Arizona License Number 9452

PROFESSIONAL EXPERIENCE

January 2005 – Present	Chief Operating Officer Nevada AIDS Research and Education Society Nevada Access to Research and Education Society Las Vegas, NV
January 2004 – Present	Chairman, Nevada ADAP Formulary Advisory Committee Nevada
July 2002 - Present	Assistant Professor Department of Pharmacy Practice University of Southern Nevada College of Pharmacy Las Vegas, NV
June 2000 – Present	Ad hoc Member University Medical Center Family Practice Committee
March 1999 - 2004	Clinical Assistant Professor of Pharmacy Practice Western University of Health Sciences Pomona, California

PROFESSIONAL EXPERIENCE

1998 - Present	Director Pharmacology and Pharmaceutical Studies Nevada AIDS Research & Education Society Nevada Access to Research & Education Society Las Vegas, Nevada
June 1997 - Present	Ad hoc Member University Medical Center of Southern Nevada Family Practice Committee Las Vegas, Nevada
Nov 1995 - June 1997	Ad hoc Member University Medical Center of Southern Nevada Ambulatory Care Committee Las Vegas, Nevada
June 1995 - Present	Clinical Instructor in Pharmacy Practice Doctor of Pharmacy Clerkship Program University of Arizona, College of Pharmacy Tucson, Arizona
May 1994	AIDS Community Provider AIDS Advanced Mini-residency San Francisco, California
Sept 1993 - Present	Adjunct Clinical Professor Department of Pharmacy Practice Idaho State University, College of Pharmacy Pocatello, Idaho
Aug 1992 - Present	Clinical Assistant Professor College of Pharmacy University of New Mexico Albuquerque, New Mexico
June 1992 - Present	Clinical Assistant Professor Department of Internal Medicine University of Nevada, School of Medicine Reno, Nevada
April 1991 - Present	Clinical Pharmacist University Medical Center of Southern Nevada Las Vegas, Nevada

PROFESSIONAL EXPERIENCE

April 1991- Present	Ad hoc Member University Medical Center of Southern Nevada Pharmacy and Therapeutics Committee Las Vegas, Nevada
April 1991- Present	Ad hoc Member University Medical Center of Southern Nevada Infection Control Committee Las Vegas, Nevada
April 1991 - Nov 1995	Ad hoc Member University Medical Center of Southern Nevada Medicine Committee Las Vegas, Nevada
June 1990 - April 1991	Staff Pharmacist University Medical Center of Southern Nevada Las Vegas, Nevada
Dec 1989 - May 1990	Weekend/Relief Pharmacist Carondelet St. Joseph's Hospital Tucson, Arizona
Nov 1989 - May 1990	Relief Pharmacist Department of Health and Human Services Indian Health Service Public Health Service Indian Hospital Sells, Arizona
July 1988 - Aug 1989	Pharmacy Intern Walgreens Pharmacy Tucson, Arizona

TEACHING EXPERIENCE

July 2002 - Present	Assistant Professor Department of Pharmacy Practice University of Southern Nevada College of Pharmacy Las Vegas, NV
---------------------	---

TEACHING EXPERIENCE

August 2000 - Present	Preceptor for Pharmacy HIV Specialty Residency Program University Medical Center of Southern Nevada Las Vegas, NV
July 1995 - Present	Preceptor for Pharmacy Practice Residency Program University Medical Center of Southern Nevada Las Vegas, NV
June 1994 - Present	Preceptor for Las Vegas Area AIDS ETC Las Vegas, Nevada
Aug 1993 - Dec 1998	Postgraduate Program for Nurse Practitioner Pharmacology University of Nevada Las Vegas Las Vegas, Nevada
Aug 1992 - Present	Clinical Assistant Professor College of Pharmacy University of New Mexico Albuquerque, New Mexico
Jan 1991 - Present	Clinical Assistant Professor Department of Internal Medicine University of Nevada School of Medicine, Reno Las Vegas, Nevada
Jan 1991 - Present	Preceptor for Doctor of Pharmacy Clinical Clerkship University of Arizona College of Pharmacy Las Vegas, Nevada
Jan 1991 - Present	Preceptor for Doctor of Pharmacy Clinical Clerkship University of Idaho College of Pharmacy Las Vegas, Nevada

PROFESSIONAL AFFILIATIONS

2001 - 2004	American Academy HIV Medicine
1999 - 2004	Nevada Pharmacy Alliance
1995-Present	Member -American College of Clinical Pharmacy
1994-1995	Member - American Cancer Society Board of Director for Northwest Unit Las Vegas, Nevada
1991-Present	American Society of Health Systems Pharmacists
1991 -1997, 2006 - Present	American Society of Parenteral and Enteral Nutrition

AWARDS

2002	Las Vegas Chamber of Commerce Community Achievement Awards Medical and Health Service Finalist
2002	Lisa B Award Community Award for HIV Care Providers Nevada Chapter of Associations of Nurses in AIDS Care
2001	Nevada Pharmacy Alliance Innovative Pharmacy Practice
1999	Nevada Pharmacy Alliance Excellence in Clinical Practice
1998	Southern Nevada AHEC; Las Vegas Area AIDS Education Training Center. Outstanding Partner Award for Exceptional Service in AIDS Education
1990	Facts and Comparisons Excellence in Clinical Communication

PRESENTATIONS

Clinical Update for the Geriatric Pharmacist Workshop – Infectious Disease. American Society of Consulting Pharmacists. Apr. 2006

Living Well Client Conference, Ryan White CARE Act Title I Program. HIV Resistance and New Medications. Golden Nugget Hotel, Las Vegas, NV Mar. 2006.

Current Trends in HIV/AIDS, Medication. Nevada Academy of Family Physicians Summer CME Conference. Orleans Hotel, Las Vegas, NV Aug. 2005.

Advances in HIV Pharmacotherapy, Advances in HIV Pharmacotherapy. Pacific AIDS Education and Training Center and USC School of Pharmacy. Jun. 2004.

Resistance patterns for Videx and Atazanavir. Bristol-Myers Squibb Pharmacist Regional Advisory Meeting. Jun. 2003.

Partners in Care, HIV life cycle and medication adherence. AFAN clients and staff. Sponsored by Clark County Health District. Jun. 2003-Present.

Lunch and Learn, HIV life cycle and medication use. AFAN clients and staff. Sponsored by Merck. May 2003.

Current Trends in HIV Therapy, Emphasis on New Medications. Nevada Pharmacy Alliance Mid-Year. Las Vegas, NV Jun. 2002.

Clinicians Use of Surveillance Data in HIV Infections. State Health Department, HIV Surveillance Team Members. Las Vegas, NV May 2002.

Current Trends in HIV Therapy, Emphasis on Once Daily Regimens. AFAN Clients and Staff. Las Vegas, NV May 2002.

Sex, Drugs and Hard Bodies. AFAN Clients and Staff. Las Vegas, NV Jul 2001.

Review of the 8th Annual Antiretroviral and Opportunistic Infection Conference. AFAN Clients and Staff. Las Vegas, NV Mar 2001.

Hepatitis C, Ribavarin/Interferon and Patients on Methadone Maintenance. Effect of Drug Interactions on therapy. Nevada Area Health Education Centers, Las Vegas, NV Nov. 2000.

PRESENTATIONS

Current HIV Treatment Guidelines with Emphasis on Women's Issues. Nevada First Lady's Women Conference. Sponsored by Nevada Area Health Education Centers, The Orleans Hotel & Casino, Las Vegas, NV, September, 1999.

More lectures available by request

PUBLICATIONS

Fuller DK. Aminoglycoside nephrotoxicity following single dose cystoscopy prophylaxis. *Ann Pharmacother* 1994;28(20):1202-3.

Fuller DK. Chemical pleurodesis. *Ann Intern Med* 1994;121(2):150.

Fuller DK. Comment: cost in treating malignant pleural effusions with bleomycin. *Ann Pharmacother* 1994;28(3):407-8.

Fuller DK. Sclerotherapy of malignant pleural effusions: economic considerations. Bristol-Myers Oncology Division; Medical Education Services, January 1994.

Fuller DK. Ketorolac and gastrointestinal ulceration. *Ann Pharmacother* 1993;27(7/8):978-9.

Fuller DK. Bleomycin vs. Doxycycline: a patient oriented approach to pleurodesis. *Ann Pharmacother* 1993;27(6):794.

Fuller DK. Cefazolin versus ceftriaxone in lower respiratory tract infection. *Ann Pharmacother* 1993;27(5):653.

Levison ML, Lipsy RJ, Fuller DK. Adverse effects and drug interactions associated with fluoxetine therapy. *Ann Pharmacother* 1991;25:657-661.

RESEARCH

Ofloxacin. A Multicenter Open-Label Study to Evaluate the Safety of IV Ofloxacin in the Treatment of Bacterial Infections in Adults Phase IIIB (N93-016). Investigator, R. W. Johnson Pharmaceutical Research Institute.

A Multicenter Active-Controlled Randomization Study to Evaluate the Safety and Efficacy of Levofloxacin vs. Ceftriaxone Sodium or Cefuroxime axetil in the Treatment of Community-Acquired Pneumonia in Adults Phase II/III (K90-071). Investigator, R. W. Johnson Pharmaceutical Research Institute.

RESEARCH

Azithromycin. Oral/Intravenous Azithromycin Treatment of Cryptosporidiosis in Patients Whose Disease has not been Controlled by Conventional Therapy (066-167S). Investigator, Premier Research.

Amphotericin B Lipid Complex (ABLC) for Companionate Use (A93-D-01, 339). Investigator, The Liposomal Company, Inc.

Saquinavir. HIV Proteinase Inhibitor Saquinavir Ro 31-8959 (SV14604). Investigator, F. Hoffmann LaRoche Limited.

Saquinavir Ro 31-8959 A Continuation Protocol with Open Label Saquinavir for HIV-Infected Patients Who Have Completed a Clinical Trial with Saquinavir Treatment (SV14788). Investigator, F. Hoffmann LaRoche Limited.

Lamivudine. 3TC (Lamivudine) Open Label Program (NUCA 3004). Investigator, Glaxo, Inc.

Vistide (Cidofovir). IV Treatment IND Protocol for Relapsing Cytomegalovirus Retinitis in Patients with AIDS (GS 95120). Investigator, Gilead Sciences.

Albendazole (Eskazole) for Compassionate Use in Microsporidiosis (IND 45062). Investigator, SmithKline Beecham.

Ambisome. Compassionate Use of Ambisome for Treatment of Invasive Fungal Infections in Patients Intolerant to, or with, Disease Unresponsive to Standard Antifungal Therapy (95-0-010). Investigator, Fujisawa USA.

Nevirapine (Viramune). An Open Label Non-Randomized Trial to Evaluate the Tolerability and safety of Viramune (nevirapine) in Adult and Pediatric Patients with Progressive, Symptomatic HIV Disease. Protocol 1100.859. Investigator, Roxanne.

Viracept. Viracept Expanded Access Program (Ind# 48.124). Investigator, Auguron.

Synercid. Open Study of Synercid (Quinupristin/Delfopristin, RP 59500) for Emergency Use (Infections Due to Resistant Bacteria Treatment Failure or in Treatment Intolerant Patients). Protocol JRV 398. Investigator, Rhone-Poulenc Rorer.

RESEARCH

Indinavir (Crixivan). A Noncomparative, Multisite, Open-Label, 48-Week Study to Monitor the Safety and Tolerability of MK-0639 (Indinavir Sulfate) 800mg q8h Administered as Monotherapy or in Combination with Reverse Transcriptase Inhibitor Therapy for the Treatment of HIV-1 Infection in Advanced AIDS Patients (Patients with CD4 Counts $<50\text{cells}/\text{mm}^3$ (99-00). Investigator, Merck and Co., Inc.

Mycobutin (Rifabutin). An Open-Label Randomized Pharmacological/ Pharmacodynamic study of mycobutin (Rifabutin) monotherapy, and in combination with myambutal (Ethambutal), for prophylactic use in prevention of Mycobacterium-Avium Complex (MAC) bacteria in AIDS patients with CD4 count $\leq 100\text{mm}^3$. Investigator, Pharmacia.

A pivotal Phase III Study of MEDI-493, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, for Prophylaxis of Severe RSV Disease in Premature Infants and Infants with Bronchopulmonary Dysplasia (BPD). Protocol MI-CP0118. Investigator, MedImmune, Inc.

Nitazoxanide. Open-Label Compassionate Use of Nitazoxanide for the treatment Of Cryptosporidiosis in AIDS patients. Protocol UMD-95-009. Investigator, Unimed Pharmaceuticals.

Viracept. An Open-Label Study to Evaluate Viracept Treatment of HIV-Infected Children Who Could Benefit from a Protease Inhibitor Based on Clinical or Immunologic Status (AG1343-546). Investigator, Aguron.

A 1592U89 Open Label Protocol of Adult Patients with HIV-1 Infection (CNA/3008). Investigator, Glaxo Wellcome Research & Development.

Thalidomide. Treatment of Aphthous Ulcers in a Patient with Behcet's Syndrome, having Failed Steroid and Immunosuppressive Therapy (IND# 53,970). Investigator.

Saquinavir. A Randomized Phase IIIB Comparative Study to Evaluate Saquinavir Soft Gel Capsules (SGC) TID Regimen in Combination with two NRTI's Versus Saquinavir Soft Gel Capsules (SGC) BID Regimen in Combination with two NRTI's Versus Saquinavir Soft Gel Capsules (SGC) BID plus Nelfinavir BID plus an NRTI in HIV-1 Infected Patients (NR5520B/M51018). Investigator, F. Hoffmann-La Roche LTD.

A 1592U89 Open Label Protocol for Pediatric Patients with HIV Infection (CNA/3007). Investigator, Glaxo Wellcome Research & Development.

RESEARCH

Sustiva (efavirenz). Expanded Access Program DMP266-903 (IND# 49,465). Investigator, DuPont Merck.

Thalidomide. Treatment of Aphthous Ulcers in a Patient with Behcet's Syndrome Having Failed Steroid and Immunosuppressive Therapy (IND# 54,463). Investigator.

A Multicenter Open Label Randomized 24-Week Study to Compare the Safety and activity of Indinavir Sulfate 800mg Q8H Versus 1200mg Q12H in HIV-Infected Individuals Having Plasma Viral RNA Less Than 400 copies/ml on Concomitant Therapy with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI) 076-00. Investigator, Merck & Company.

Preveon Expanded Access Program for the Treatment of Patients with AIDS Who Have Failed Other Antiretroviral Therapy and have Limited Treatment Options (GS-52-427). Investigator, Gilead Sciences.

An Open-Label Multicenter Study to Assess the Safety and Antiviral Activity of a Twice-Daily Dosing Regimen of Viracept Combined with Two Reverse Transcriptase Inhibitors in HIV-Infected, Treatment Naive Patients (AG13543-1022). Investigator, Auguron

Compassionate Use of Thalidomide in Hypocomplementemic Urticarial Vasculitis Syndrome (IND 55,590), Investigator.

The Thalidomide Compassionate Use Program. Compassionate Use of Thalidomide in Adults with HIV-Associated Wasting (W-002). Investigator, Celgene Corp (1998).

Amprenavir (141W94). Open label protocol for patients with HIV-1 infection who have experienced treatment failure or are intolerant to protease therapy, (PR030010). Investigator, Glaxo Wellcome, Dec., 1998.

A Phase III trial to determine efficacy of bivalent AIDSVAX™ B/B vaccine in adults at risk for sexually transmitted HIV-1 infection in North America (VAX004). Investigator, Vaxgen Inc., March, 1999.

Evaluation of the safety and antiviral activity of stavudine extended release Formulation as compared to stavudine immediate release formulation, each as part of potent antiretroviral combination therapy. (AI455-096). Investigator, Bristol-Myers Squibb, Oct 1999.

RESEARCH

DE 009. A multicenter randomized placebo controlled phase II study of the Human Anti-TNF Antibody D2E7 administered as subcutaneous injections in rheumatoid arthritis patients treated with methotrexate. (LU 200134).

Investigator, Knoll Pharmaceutical Comp, Dec 1999.

O99009 Transdermal oxybutynin in patients with urge urinary incontinence: A 12 week multicenter, randomized, double-blind, placebo-controlled study with a 12-week open-label, dose-titration, safety extension. Watson Laboratories.

Investigator, Jan 2000.

Protocol M99-046. ABT-378/r (ABT-378/ritonavir) Early Access Program.

Investigator, Abbott Laboratories, Jan 2000.

Protocol ESS 40001 A Phase IV, open-label, randomized study to compare the efficacy and safety of Epivir/Ziagen/Zerit versus Epivir/Ziagen/Sustiva versus Epivir/Ziagen/Agenerase/Norvir for 96 weeks in the treatment of HIV-1 infected subjects who are Antiretroviral therapy naive. Glaxo Wellcome. Investigator, Aug 2000.

Protocol ESS 40009 Ziagen Optimal Regimen and Resistance Observational Study. A Phase IV, Open-label study to assess the safety and tolerability of abacavir (Ziagen), in HIV-1 infected individuals and to investigate the effect of baseline genotype with virtual phenotype on the response to abacavir (Ziagen) in therapy experienced subjects in the clinical setting. GlaxoWellcome Research and Development. Investigator, Aug 2000.

HMP-3006 A Study of the Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release (HHER) Compared to Placebo in Patients with Chronic Pain. Purdue Pharma L.P. Investigator. Jan 2001.

AI455-110. A Study to Compare Stavudine (D4T) Extended Release (ER) versus Conventional (Immediate Release, IR) Formulations, Each in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Subjects who have Completed BMS Studies AI455-096 and AI455-099. Bristol-Myers Squibb. Investigator Jan 2001.

ESS40013. A Phase IV Multicenter Study of the Efficacy and Safety Of 48-Week Induction Treatment with Trizivir + Efavirenz Followed by 48-Week Randomized, Open-Label Maintenance Treatment with Trizivir ± Efavirenz in HIV-1 Infected ART Naïve Subjects. GlaxoSmithKline. Investigator Mar 2001.

HIV-TE-Evaluation Project 101. An Evaluation of the Use of the HIV-Therapy Edge (HIV-TE) Service in the Management of HIV-Positive Patients Currently Failing Antiretroviral Drug Therapy. Intelligent Therapeutic Solutions, Inc. Investigator May 2001.

RESEARCH

O00011. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing Oxybutynin Transdermal Systems versus Tolterodine Long Acting Capsules in Patients with Overactive Bladder. Watson Laboratories. Investigator May 2001.

CNA30021. A phase III, 48 week, randomised, double-blind, multicentre study to evaluate the safety and efficacy of abacavir (ABC) 600mg once-daily(QD) vs abacavir 300mg BID in combination with lamivudine (3TC) (300mg QD) and efavirenz (EFV) (600mg QD) in antiretroviral therapy Naive HIV-1 infected subjects. GlaxoSmithKline. Investigator November 2001.

M016455P/3003. A multicenter, open label, randomized, parallel group study to assess the long term safety, performance, and efficacy of fexofenadine compared to montelukast in subjects with asthma. Aventis. Investigator April 2002.

AI424-045. A randomized, open label study of the antiviral efficacy and safety of atazanavir, in combination with ritonavir or saquinavir, and the combination of lopinavir each with tenofovir and a nucleoside in subjects who have experienced virologic failure. Bristol-Myers Squibb. Investigator April 2002.

CFOR258D2307. A randomized, multicenter, placebo controlled, parallel group study, of four month duration per patient, to evaluate the safety and efficacy of treatment with 24mcg bid and 12mcg bid formoterol double blind and 12mcg bid formoterol with additional on demand formoterol doses open label in adolescent and adult patients with persistent stable asthma. Novartis. Investigator April 2002.

BI1182.52. Double-blind, randomized, dose optimization trial of three doses of tipranavir boosted with low dose ritonavir (TPV/RTV) in multiple antiretroviral drug-experienced subjects. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. May 2002.

AI424900. Atazanavir (BMS-232632) for HIV infected individuals: An early access program. Bristol-Myers Squibb. Investigator. July 2002.

MEM-MD-06. Evaluation of the long term safety and efficacy of memantine in the treatment of chronic pain in patients with painful diabetic neuropathy. Forest Laboratories. Investigator. June 2002.

ZOL446H2310 (zoledronic acid). Multinational, multicenter, double-blind, randomized, placebo controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fractures after a hip fracture. Novartis. Investigator. June 2002.

RESEARCH

BI1182.17. A long term open label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir use in HIV-1 infected subjects. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator August 2002.

MV16812. Multicenter, open-label, early access program of fuzeon (enfuvirtide) T-20/Ro29-9800, HIV-1 Fusion Inhibitor) in combination with free choice antiretroviral regimen to assess serious adverse events, serious AIDS defining events, and tolerability in patients with advanced HIV-infection. F. Hoffmann-LaRoche LTD, Trimeris Inc., Investigator.

BI1182.12. Randomized, open-label, comparative safety and efficacy study of tipranavir boosted with low-dose ritonavir (TPV/RTV) versus genotypically-defined protease inhibitor/ritonavir (PI/RTV) in multiple antiretroviral drug-experienced patients (RESIST-1: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir). Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. Jan 2003.

BI1182.51. An open label, randomized, parallel group pharmacokinetics trial of tipranavir/ritonavir (TPV/RTV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimized background regimen, in multiple antiretroviral (ARV) experienced patients. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. Jan 2003.

BY217/M2-023. A randomized controlled study of roflumilast (250mcg and 500mcg) versus placebo in patients with asthma. A 24 week, multicenter, multinational, double-blind, parallel group clinical study. Altana. Investigator. 2003.

D5896C0005. A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT[®] pMDI administered either as fixed or as an adjustable regimen versus a fixed regimen of Advair[™] in subjects 12 years of age and older with asthma. Astra Zeneca. Investigator. 2003.

BI1182.58. An open label safety study to evaluate the safety of tipranavir plus ritonavir when used in combinations with other agents for the treatment of patients with HIV infection who have failed and/or are intolerant to combination antiretroviral therapy and have limited treatment options. Boehringer Ingelheim. Investigator. April 2004.

RESEARCH

NN210005. A phase I, multicenter, randomized, parallel, double-blinded dose ranging, placebo-controlled study to compare antiviral effect, safety, tolerability and pharmacokinetics of four oral dosage regimens of GW695634G monotherapy versus placebo over 7 days in NNRTI-experienced HIV-1 infected adults. GlaxoSmithKline. Investigator. July 2004.

COL102060. An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination with Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects Over 48 Weeks. GlaxoSmithKline. Investigator. October 2004.

Protocol ML18018: A 12-Week, Prospective, Open-label, Multicenter, Cohort Study to Assess HIV-Patient QUALity of LIfe and Tolerability After Administration of Enfuvirtide-Containing HAART (QUALITE). Roche. Investigator. December 2004.

BI1182.70. An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered with Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients with HIV-1 Infection (the Tipranavir Expanded Access Program). Boehringer Ingelheim. Investigator. December 2004.

CCR102881. A Phase IIb, 96 week, randomised, partially double-blinded, multicentre, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with COMBIVIR (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults. GlaxoSmithKline. Investigator. March 2005.

CCR104627. A screening protocol to determine eligibility for one of three Phase III treatment studies evaluating the efficacy and safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 infected, treatment-experienced subjects with drug-resistant virus or an observational study in X4-tropic or non-phenotypeable HIV-1 infected, treatment-experienced subjects with drug-resistant virus. GlaxoSmithKline. Investigator. July 2005.

HPR20001. A phase IIb, randomized, multicenter, parallel group study to evaluate the short-term safety, pharmacokinetics and antiviral activity of four blinded dosing regimens of GW640385/ritonavir therapy compared to open-label current protease inhibitor therapy in HIV-1 infected, protease inhibitor experienced adults for 2 weeks with long-term evaluation (>48 weeks) of safety, pharmacokinetic and antiviral activity of selected GW640385/ritonavir dosing regimen(s) vs. a ritonavir-boosted, protease inhibitor containing regimen. GlaxoSmithKline. Investigator. October 2005.

RESEARCH

TMC114-C211. A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. ARTEMIS TRIAL. Tibotec Pharmaceuticals Ltd. Investigator. November 2005.

TMC114-C226. Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. Tibotec Pharmaceuticals Ltd. Investigator. November 2005.

References available upon request